Michael L. Miller

3.8k total citations · 1 hit paper
68 papers, 2.7k citations indexed

About

Michael L. Miller is a scholar working on Oncology, Organic Chemistry and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael L. Miller has authored 68 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 20 papers in Organic Chemistry and 19 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael L. Miller's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Cancer Treatment and Pharmacology (9 papers). Michael L. Miller is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Cancer Treatment and Pharmacology (9 papers). Michael L. Miller collaborates with scholars based in United States, Canada and United Kingdom. Michael L. Miller's co-authors include Ravi Chari, Wayne C. Widdison, Yi Shi, Anthony J. Di Pasqua, Iwao Ojima, J. P. Heppner, Xudong Geng, Songnian Lin, Cristian Vaccari and Rajeeva Singh and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Michael L. Miller

64 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

2014 759 citations Ravi Chari, Michael L. Miller et al. Angewandte Chemie International Edition profile →

Peers

Countries citing papers authored by Michael L. Miller

Since Specialization

Citations

This map shows the geographic impact of Michael L. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Miller more than expected).

Fields of papers citing papers by Michael L. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Miller. The network helps show where Michael L. Miller may publish in the future.

Co-authorship network of co-authors of Michael L. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Miller. A scholar is included among the top collaborators of Michael L. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Miller. Michael L. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Defective glycosylation and ELFN1 binding of mGluR6 congenital stationary night blindness mutants 2024 ·Life Science Alliance ·(unknown), (unknown), Jae Eun Lee, Michael L. Miller, (unknown), (unknown), Melina A. Agosto	1
2	Complex N-glycosylation of mGluR6 is required for trans-synaptic interaction with ELFN adhesion proteins 2024 ·Journal of Biological Chemistry ·Michael L. Miller, (unknown), Melina A. Agosto	2
3	Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy 2020 ·Molecular Cancer Therapeutics ·Jose F. Ponte, Leanne Lanieri, Eshita Khera, Rassol Laleau, Olga Ab, Christopher W. Espelin, Neeraj Kohli, (unknown), Yulius Y. Setiady, Michael L. Miller, Thomas A. Keating, Ravi Chari, Jan Pinkas, Richard J. Gregory, Greg M. Thurber	29
4	Digital Threats to Democracy: Comparative Lessons and Possible Remedies 2020 ·The International Journal of Press/Politics ·Michael L. Miller, Cristian Vaccari	46
5	A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity 2016 ·Molecular Cancer Therapeutics ·Michael L. Miller, Nathan Fishkin, Wěi Li, Kathleen R. Whiteman, Yelena Kovtun, (unknown), Katie E. Archer, Erin K. Maloney, Charlene A. Audette, Michele Mayo, Alan Wilhelm, (unknown), Rajeeva Singh, Jan Pinkas, Victor S. Goldmacher, John M. Lambert, Ravi Chari	65
6	Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy breakdown → 2014 ·Angewandte Chemie International Edition ·Ravi Chari, Michael L. Miller, Wayne C. Widdison	759
7	Platinum(IV) cisplatin derivative trans, cis, cis-bis(heptanoato)amine(cyclohexylamine)dichloridoplatinum(IV) has an enhanced therapeutic index compared to cisplatin for the treatment of non-small cell lung cancer 2014 ·Inorganica Chimica Acta ·Yi Shi, Bhuvaneswari Koneru, (unknown), Michael L. Miller, Lara Myers, Anthony J. Di Pasqua	6
8	Arrival time and magnitude of airborne fission products from the Fukushima, Japan, reactor incident as measured in Seattle, WA, USA 2011 ·Journal of Environmental Radioactivity ·J. Leon, Daniel A. Jaffe, J. Kašpar, A. Knecht, Michael L. Miller, R. G. H. Robertson, A. Schubert	111
9	Intrinsic enzymatic crosslinking and maturation of the in situ pellicle 2008 ·Archives of Oral Biology ·Christian Hannig, Bettina Spitzmüller, Michael L. Miller, Elmar Hellwig, Matthias Hannig	34
10	Folate Receptor–Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate 2007 ·Cancer Research ·Joseph A. Reddy, Elaine Westrick, Hari Krishna R. Santhapuram, Stephen Howard, Michael L. Miller, Marilynn Vetzel, Iontcho R. Vlahov, Ravi Chari, Victor S. Goldmacher, Christopher P. Leamon	67
11	Design, Synthesis and Structure−Activity Relationships of Novel Taxane-Based Multidrug Resistance Reversal Agents 2005 ·Journal of Medicinal Chemistry ·Iwao Ojima, Christopher P. Borella, (unknown), Pierre‐Yves Bounaud, (unknown), Matthew B. Sturm, Michael L. Miller, Subrata Chakravarty, Jin Chen, (unknown), Paula Pera, Tracy A. Brooks, Maria R. Baer, Ralph J. Bernacki	28
12	Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies 2004 ·Bioorganic & Medicinal Chemistry Letters ·Michael L. Miller, (unknown), (unknown), Barbara A. Leece, Victor S. Goldmacher, Ravi Chari, Iwao Ojima	11
13	Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Erkan Baloglu, Michael L. Miller, (unknown), (unknown), Barbara A. Leece, Victor S. Goldmacher, Ravi Chari	15
14	Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery 2004 ·Journal of Medicinal Chemistry ·Michael L. Miller, (unknown), Robert Y. Zhao, Barbara A. Leece, Olga Ab, Erkan Baloglu, Victor S. Goldmacher, Ravi Chari	19
15	Synthesis of Novel C2−C3‘N-Linked Macrocyclic Taxoids by Means of Highly Regioselective Heck Macrocyclization 2003 ·Organic Letters ·Xudong Geng, Michael L. Miller, Songnian Lin, Iwao Ojima	40
16	Synthesis and structure-activity relationships of new second-generation taxoids 1999 ·Bioorganic & Medicinal Chemistry Letters ·Iwao Ojima, Tao Wang, Michael L. Miller, Songnian Lin, Christopher P. Borella, Xudong Geng, Paula Pera, (unknown)	60
17	A Convenient Synthesis of 2,2,4-Trimethylcyclohexane-1,3-Dione: A Useful Precursor for The Taxoid a Ring 1997 ·Synthetic Communications ·Michael L. Miller, Partha S. Ray	2
18	Dynamics of the CRRES barium releases in the magnetosphere 1994 ·Journal of Geophysical Research Atmospheres ·S. A. Fuselier, S. B. Mende, S. P. Geller, Michael L. Miller, R. A. Hoffman, J. R. Wygant, M. B. Pongratz, Nigel P. Meredith, R. R. Anderson	5
19	Thrombotic thrombocytopenic purpura in a patient with AIDS 1990 ·Cleveland Clinic Journal of Medicine ·Glenn H. Segal, Raymond R. Tubbs, Norman B. Ratliff, Michael L. Miller, David L. Longworth	14
20	Search for auroral belt E_∥ fields with high‐velocity barium ion injections 1989 ·Journal of Geophysical Research Atmospheres ·J. P. Heppner, B. G. Ledley, Michael L. Miller, (unknown), M. B. Pongratz, D. W. Slater, T. J. Hallinan, D. Rees	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact